Eli Lilly and Company Expands Authorized Generic Agreements with Prasco®

- Prasco to market the Authorized Generic of EVISTA® in the United States

CINCINNATI, April 1, 2014 /PRNewswire/ -- Prasco Laboratories, announced today it has signed a marketing and distribution agreement with Eli Lilly and Company (NYSE: LLY) to market the Authorized Generic (AG) version of EVISTA® (raloxifene hydrochloride tablets), in 60 mg strength in the United States.  Prasco will begin shipping the product immediately.  The financial terms of the agreement were not disclosed.

"Prasco continues to demonstrate our passion to bring high-quality, low-cost prescription drugs to consumers," said Prasco president and chief operating officer, David Vucurevich, R.Ph.  "EVISTA represents our third Eli Lilly and Company Authorized Generic product launched, and we are very pleased to broaden that relationship.

"Prasco's Authorized Generic products ensure consistent supply to customers and pharmacists.  Additionally, our AG products allow patients to continue their therapy using the same brand with which they are accustomed, but at a generic cost savings," Vucurevich concluded.

EVISTA® is an estrogen agonist/antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women; Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis; Reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.  Important Limitations:  EVISTA is not indicated for the treatment of invasive breast cancer, reduction of the risk of recurrence of breast cancer, or reduction of risk of noninvasive breast cancer.

You should not take EVISTA if you have had or are at risk for getting blood clots in the legs, lungs or eyes, as it may increase the risk of blood clots. Stop taking EVISTA and call your doctor if you have leg pain or warmth, swelling of the legs, hands or feet, chest pain, shortness of breath or a sudden vision change, as these may be signs of a blood clot. Being unable to move around for long periods may increase this risk. If you will need to be still for a long time, talk to your doctor about ways to reduce the risk of blood clots. 

 

EVISTA does not increase the risk of a heart attack or stroke in women who have had or are at risk for a heart attack; however; EVISTA increases the likelihood of dying from stroke in these women, should one occur. Before taking EVISTA tell your doctor if you have had a stroke, a mini-stroke, irregular heartbeat, high blood pressure, heart attack, history of smoking, or believe you have other risk factors for stroke or a heart attack.

 

For additional information about EVISTA, please see Full Prescribing Information and Medication Guide at http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020815s018lbl.pdf.

About Prasco Laboratories – Prasco, the Authorized Generic Company, is the privately held healthcare company located in Mason, Ohio. The leader in Authorized Generics, Prasco has more AG partnerships than any other company.  Established brand companies rely on Prasco to bring their brand products to the generic marketplace as Authorized Generics, which offers alternatives to consumers and pharmacists.  For more information, visit www.prasco.com.

RALX-1007

SOURCE Prasco Laboratories

Suggested Articles

Johnson & Johnson and Bayer’s Xarelto is working to reverse a sales slide, and a new indication could help.

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

To get its $12 billion opioid deal off the ground, Purdue Pharma pushed for a stay on thousands of lawsuits against it. Last week, a judge signed off.